Molecular Characteristics Molecular Type: Synthetic pentadecapeptide research compound Structure: Linear peptide chain (15 amino acids) Stability: High when stored under recommended laboratory conditions Molecular Weight: Sequence-dependent Stability Characteristics and Storage Guidance Supplied as a lyophilized powder for long-term molecular stability Recommended storage: 20C for extended preservation Sensitive to humidity and prolonged light exposure Predictable degradation above room temperature Reconstituted solutions remain stable for approximately 2448 hours under refrigeration Solubility and Experimental Handling Bacteriostatic water Sterile saline solutions Acidic laboratory buffers Compatible analytical-grade organic solvents Technical Overview product Name BPC-157 15mg cas 137525-51-0 purity 99% (HPLC verified) unit Size 15 mg vial form Lyophilized research powder synthesis Solid-Phase Peptide Synthesis (SPPS) analytical HPLC, Mass Spectrometry, UV Spectrophotometry molecular Structure Linear synthetic peptide chain stability High under appropriate laboratory storage Quality Assurance and Analytical Control High-Performance Liquid Chromatography (HPLC) purity verification Mass Spectrometry (MS) molecular identity and sequence confirmation UV spectrophotometric concentration assessment Batch consistency and reproducibility checks Endotoxin and microbial screening for research suitability Regulatory Position and Intended Use BPC-157 15mg is supplied strictly for laboratory research and scientific investigation
Such pH adjusting agents and buffers are included in an amount required to maintain pH of the formulation from a pH of about 5 to about 9, in one embodiment a pH from about 6.5 to about 7.5, and in yet another embodiment at a pH of about 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0
We are not aware of any information to indicate that Amanita muscaria is the subject of a prior sanction (see 21 CFR Part 181)
Diabetic patients on insulin or sulfonylureas should monitor blood glucose closely when combining MIC injections with calorie restriction, as the combined effect can increase hypoglycemia risk during the first 23 weeks of treatment
